|Bid||64.89 x 200|
|Ask||64.83 x 100|
|Day's Range||62.80 - 64.82|
|52 Week Range||58.33 - 108.25|
|Beta (3Y Monthly)||1.72|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 13, 2019 - Feb 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||84.00|
Incyte Corporation announced today that it will present at Evercore ISI HEALTHCONx on Wednesday, November 28, 2018 at 3:30 pm EST in Boston.
Exelixis (EXEL) reported net income of $126.6 million in the third quarter compared to $81.4 million in the third quarter of 2017. The company’s net income over the first nine months of this year amounted to $330.0 million compared to $115.7 million in the same period the prior year.
NEW YORK, Nov. 05, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Results of REACH1 trial evaluating ruxolitinib in patients with steroid-refractory acute graft-versus-host disease accepted as an oral presentation
Gilead Sciences (NASDAQ:GILD) fell 5.4% after UnitedHealth Group (NYSE:UNH) unveiled a new plan that favors lower-cost HIV treatments, putting Gilead’s core business in the crosshairs. Rather, investors may want to take a closer look at Walmart (NYSE:WMT), Prologis (NYSE:PLD) and Incyte (NASDAQ:INCY). Walmart has been one of the market’s bigger winners since June, up more than 20% in that short timeframe.
NEW YORK, NY / ACCESSWIRE / November 1, 2018 / U.S. equities rose on Wednesday as a number of high profile companies reported upbeat corporate earnings that helped boost investor confidence. The Dow Jones ...
Incyte (INCY) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.14 on revenues of $449.68 million in the third quarter of 2018, compared to estimates for EPS of $0.40 on revenues of $449.20 million.
Incyte (INCY) delivered earnings and revenue surprises of -5.00% and -3.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Wilmington, Delaware-based company said it had profit of 14 cents. Earnings, adjusted for stock option expense and non-recurring costs, were 38 cents per share. The results fell ...
WILMINGTON, Del.-- -- Total product-related revenues of $430 million for the three months and $1.2 billion for the nine months ended September 30, 2018; Jakafi ® revenues of $348 million in 3Q 2018 and $1.0 billion YTD 2018 sNDA for ruxolitinib for the treatment of patients with steroid-refractory acute graft versus host disease accepted by the FDA for Priority Review Compelling data from pemigatinib ...
Wall Street analysts estimate Incyte’s (INCY) revenues will increase by ~17.7% to $449.2 million during the third quarter of 2018 compared to revenues of $381.5 million during the third quarter of 2017. Also, the earnings per share are estimated to be $0.40 for the third quarter of 2018 as compared to earnings per share of $0.08 for the third quarter of 2017. Incyte stock has fallen nearly 46.6% over the last 12 months and decreased by ~35.7% in 2018 year-to-date.
As discussed earlier, analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018. The below graph compares the revenues of Incyte since the first quarter of 2017 and estimates for the third quarter of 2018. Incyte’s revenue stream includes product sales, royalty revenues, and other revenues from collaborations. Incyte acquired the commercial rights for Iclusig from Ariad Pharmaceuticals in 2016.
Incyte Corporation (INCY) announced today that it has been named one of the global biotechnology and pharmaceutical industry’s top employers by Science magazine, ranking second on the list of only 20 companies recognized in the publication’s annual Top Employer’s Survey. “We are proud to be recognized as the number two top employer in the biopharma industry by Science magazine and, importantly, also by our own team,” said Hervé Hoppenot, Chief Executive Officer, Incyte. The Science and Science Careers’ 2018 annual Top Employers Survey polled employees in biotechnology, pharmaceutical and related industries to determine the 20 best employers in these industries as well as their driving characteristics.
Incyte Corporation (INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi®) for the treatment of patients with acute graft-versus-host-disease (GVHD) who have had an inadequate response to corticosteroids. The FDA grants Priority Review to medicines that have the potential to provide significant improvements in the treatment of a serious disease. This designation shortens the FDA review period to six months compared to 10 months for Standard Review.
Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q3 results on Oct 30.